Taner 2006.

Methods	Eight‐week single‐blind randomised study
Participants	Outpatients fulfilling DSM‐IV criteria for major depressive disorder lasting at least 1 month and for atypical depression. Exclusion criteria: significant suicide risk, pregnancy, lactation or unwillingness to use effective birth control in women, unstable and serious physical illness, a history of seizures, psychosis or organic mental syndrome, substance abuse disorders within the past 6 months, except for nicotine dependence, history of mania, antisocial personality disorder and use of an antidepressant over the previous month.
Interventions	Fluoxetine: 21 participants Reboxetine: 22 participants Fluoxetine dose range: 40‐80 mg/day Reboxetine dose range: 4‐10 mg/day
Outcomes	Change in the Hamilton Rating Scale for Depression‐17 item (HDRS‐17) score and in Clinical Global Impression (CGI) score
Notes	Funding: unclear
Risk of bias
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	Randomised, no further information
Allocation concealment (selection bias)	Unclear risk	No information provided
Blinding (performance bias and detection bias) All outcomes	High risk	Single blind, no further information
Blinding of participants and personnel (performance bias) All outcomes	High risk	Quote: "both psychiatrists, one rated the tests and the other who performed the drug follow‐up, were blinded to each other until the end of the study", no further information
Blinding of outcome assessment (detection bias) All outcomes	High risk	Single blind, no further information
Incomplete outcome data (attrition bias) All outcomes	High risk	Number and reasons for dropout reported, mean endpoint scores (HDRS‐17, CGI, Global Assessment of Functioning [GAF]) reported, but data in the text was different from tables
Selective reporting (reporting bias)	High risk	Side effects were described, but the whole number of patients reporting side effects was unclear
Other bias	Unclear risk	Funding: unclear